
    
      A double-blind, placebo-controlled, randomized single dose escalation study and a
      double-blind, placebo-controlled, randomised parallel group 14-days once daily repeat dose
      study to investigate safety, tolerability and pharmacokinetics of an intranasal H1/H3 dual
      antagonist compound in healthy male subjects.
    
  